Sofpironium bromide is a new chemical entity that we are currently developing in the U.S. as a potential best-in-class, self-administered, once-daily, topical therapy for the treatment of primary axillary hyperhidrosis, or excessive underarm sweating.
In October 2021, we announced positive topline results from the U.S. Phase 3 pivotal clinical program for sofpironium bromide gel, 15%, in which all primary and secondary endpoints were met and achieved statistical significance. Sofpironium bromide gel, 15% was generally well tolerated. The U.S. Phase 3 pivotal clinical program was comprised of two pivotal clinical studies, Cardigan I and Cardigan II. The studies were multicenter, randomized, double-blinded, vehicle (placebo)-controlled, evaluating the efficacy and safety of topically applied sofpironium bromide gel, 15%. Each Cardigan study enrolled approximately 350 subjects nine years of age and older with primary axillary hyperhidrosis, and subjects applied sofpironium bromide gel, 15% or placebo to their underarms once daily at bedtime for six consecutive weeks, with a two-week post-treatment follow-up. Based on the results from the Phase 3 pivotal program, we expect to submit a New Drug Application (NDA) for sofpironium bromide gel, 15% to the U.S. FDA in mid-2022.
In addition, in September 2020 our development partner, Kaken Pharmaceutical Co., Ltd., received regulatory approval to manufacture and market sofpironium bromide gel, 5% under the brand name ECCLOCK® for the once-daily treatment of primary axillary hyperhidrosis in Japan. Kaken launched ECCLOCK commercially in November 2020, marking the first commercialization of sofpironium bromide for any indication worldwide.
Sofpironium bromide was designed as a structural analog of a well-known potent anticholinergic, glycopyrrolate, to achieve its therapeutic effect at the application site (skin) similar to glycopyrrolate. However, it differs from glycopyrrolate in that sofpironium bromide was retrometabolically designed.